Cancer metastatic colorectal. STUDIU: Imunoterapia cu nivolumab+ipilimumab, eficientă pentru cancerul colorectal MSI-H sau dMMR
Our study included patients with metastatic CRC that received chemotherapy ± bevacizumab, from January until December Patients received fluropirimidine-based chemotherapy plus or minus bevacizumab.
No significant differences was registered between groups with respects of age, sex, tumor localization, chemotherapy regimen used. Also no significant difference was found in our groups regarding risk factors for bleeding and medical history.
No remarkable differences were registered between the two groups regarding common adverse reactions to chemotherapy, with the exception of physical asthenia which was found in a greater proportion of patients that received bevacizumab in combination with chemotherapy.
In our study most frequent adverse events related to bevacizumab were cancer metastatic colorectal 1 or 2, only few cancer metastatic colorectal events were grade 3 or 4 and lead to discontinuation of bevacizumab treatment, and these were mainly thromboembolic events and bleeding.
Keywords: metastatic colorectal cancer; bevacizumab; chemotherapy; adverse events Issue:Volume 71, Issue 1 Pages: